Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: A naturalistic study

Bernardo Dell'Osso, Chiara Arici, Cristina Dobrea, Giulia Camuri, Beatrice Benatti, A. Carlo Altamura

Research output: Contribution to journalArticle

Abstract

Background: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders. Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy. Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antipsychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed. Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalNeuropsychiatric Disease and Treatment
Volume9
DOIs
Publication statusPublished - Feb 7 2013

Fingerprint

Citalopram
Mood Disorders
Therapeutics
Major Depressive Disorder
Serotonin Uptake Inhibitors
Sleep Initiation and Maintenance Disorders
Dizziness
Group Psychotherapy
Anxiety Disorders
Bipolar Disorder
Nausea
Antidepressive Agents
Antipsychotic Agents
Observation
Safety

Keywords

  • Affective disorders
  • Augmentative therapy
  • Escitalopram
  • Monotherapy
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders : A naturalistic study. / Dell'Osso, Bernardo; Arici, Chiara; Dobrea, Cristina; Camuri, Giulia; Benatti, Beatrice; Altamura, A. Carlo.

In: Neuropsychiatric Disease and Treatment, Vol. 9, 07.02.2013, p. 205-209.

Research output: Contribution to journalArticle

@article{97838cfab52249c18b3b847a63669953,
title = "Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: A naturalistic study",
abstract = "Background: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders. Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy. Results: Sixty-seven (51.1{\%}) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9{\%}) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5{\%}), mood stabilizers (33.4{\%}), and atypical antipsychotics (30.1{\%}). Side effects were reported in 5.3{\%} of the total sample and the most common were insomnia (2.3{\%}), nausea (2.3{\%}), and dizziness (0.8{\%}). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed. Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.",
keywords = "Affective disorders, Augmentative therapy, Escitalopram, Monotherapy, Tolerability",
author = "Bernardo Dell'Osso and Chiara Arici and Cristina Dobrea and Giulia Camuri and Beatrice Benatti and Altamura, {A. Carlo}",
year = "2013",
month = "2",
day = "7",
doi = "10.2147/NDT.S39322",
language = "English",
volume = "9",
pages = "205--209",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders

T2 - A naturalistic study

AU - Dell'Osso, Bernardo

AU - Arici, Chiara

AU - Dobrea, Cristina

AU - Camuri, Giulia

AU - Benatti, Beatrice

AU - Altamura, A. Carlo

PY - 2013/2/7

Y1 - 2013/2/7

N2 - Background: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders. Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy. Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antipsychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed. Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.

AB - Background: Escitalopram is a selective serotonin reuptake inhibitor, widely used in the treatment of affective disorders. The purpose of this study was to examine its safety and tolerability, as mono- versus augmentative therapy, in a group of patients with affective disorders. Materials and methods: The sample consisted of 131 patients suffering from different affective disorders, including major depressive disorder, bipolar disorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks. Data were analyzed on the basis of mono- versus augmentative therapy, as well as age, gender, mean daily dosage, and patterns of combination therapy. Results: Sixty-seven (51.1%) patients were treated with monotherapy (mean dose of 11.76 mg/day) and 64 (48.9%) with augmentative escitalopram (mean dose of 12.81 mg/day). The mean duration of escitalopram treatment was 14 months. The most frequently combined compounds were: other antidepressants (36.5%), mood stabilizers (33.4%), and atypical antipsychotics (30.1%). Side effects were reported in 5.3% of the total sample and the most common were insomnia (2.3%), nausea (2.3%), and dizziness (0.8%). No significant difference, in terms of tolerability, in mono- versus augmentative therapy groups was found. In addition, neither age nor gender was significantly correlated with a greater presence of side effects. Finally, no significant correlation between dosage and side effects was observed. Conclusion: Over a 14-month observation period, escitalopram, either as monotherapy or an augmentative treatment, was found to be well tolerated in a large sample of patients with affective disorders, with an overall low rate of side effects.

KW - Affective disorders

KW - Augmentative therapy

KW - Escitalopram

KW - Monotherapy

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84873702641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873702641&partnerID=8YFLogxK

U2 - 10.2147/NDT.S39322

DO - 10.2147/NDT.S39322

M3 - Article

C2 - 23429980

AN - SCOPUS:84873702641

VL - 9

SP - 205

EP - 209

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -